This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Zaino, R. J. Articles by Satyaswaroop, P. G. Search for Related Content PubMed PubMed Citation Articles by Zaino, R. J. Articles by Satyaswaroop, P. G.

Heterogeneity of Progesterone Receptor Distribution in Human Endometrial Adenocarcinoma¹

Departments of Pathology [R. J. Z.] and Obstetrics and Gynecology [C. L. C., R. M., P. G. S.], The Milton S. Hershey Medical Center, The Pennsylvania State University, Hershey, Pennsylvania 17033

The clinical response of advanced endometrial adenocarcinoma to progestin therapy does not correlate perfectly with biochemically assayed progesterone receptor status of the tumor. We have previously suggested that heterogeneity of progesterone receptor at the cellular, tumor, and tissue levels, not detectable by the biochemical assay, might contribute to this discrepancy. A monoclonal antibody, hPRa-1, generated against human progesterone receptor, was used in the present study to immunohistologically define the heterogeneity of progesterone receptor distribution in primary endometrical carcinomas. Twenty-four hysterectomy specimens removed for the treatment of endometrial adenocarcinoma were examined by biochemical assay of progesterone receptor and immunohistochemistry. In two cases, in which tumor occupied almost all of the endometrial lining, more extensive sampling was performed with removal of four noncontiguous sites. Each site was subdivided for immunohistochemistry and biochemical assay of progesterone receptor. When present, progesterone receptor localization was confined to the nuclei of target cells. Variability in the distribution and intensity of staining was consistently observed within the tumors. Of 24 tumors 15 were determined to be progesterone receptor positive by biochemical assay, while 12 of 24 tumors displayed immunolocalization for progesterone receptor. The correlation of the results by the two methods was high (20 of 24 cases, 83%), and the discrepancies in three cases appeared to reflect tissue and tumor heterogeneity. Immunolocalization has demonstrated that heterogeneity is present at the tumor, tissue, and cellular level within endometrial carcinomas, and the failure of some progesterone receptor-positive (by biochemical assay) tumors to respond to progestin therapy may reflect false positive results due to contamination of progesterone receptor-negative tumors by adjacent benign endometrium or myometrium.

¹ Supported by National Cancer Institute Grant P01-CA40011 and by NIH Grant HD 14702.

² To whom requests for reprints should be addressed.

³ Present address: Garvan Institute of Medical Research, St. Vincent's Hospital, Darlinghurst NSW 2000, Australia.

Received 8/ 3/87. Revised 11/17/87. Accepted 12/16/87.

This article has been cited by other articles:

				G. Fons, S. M Hasibuan, J. van der Velden, and F. J W ten Kate Validation of tissue microarray technology in endometrioid cancer of the endometrium J. Clin. Pathol., May 1, 2007; 60(5): 500 - 503. [Abstract] [Full Text] [PDF]